Obstructive sleep apnea is readily reversible with nasally administered continuous positive airway pressure, although its effectiveness can be limited by poor patient compliance with therapy. With recent developments in technology, the ability to both diagnose and manage this disorder is dramatically improving.Assessmentand therapelitic intervention can now be carried out not only in attended settings , such as sophisticated sleep laboratories, but in semiattended and unattended situations, including the home. What impact these advances will have on improving patient tolerance to therapy and reducing long-term clinical consequences ofobstructive sleep apnea remains to be seen. However, there is no doubt that sleep-trained professionals now have many more tools at their disposa l to diagnose and treat this disorde r.
Introduction
Obstructive sleep apnea (OSA) is charac terize d by repetitive collapse of the upper airway during sleep. The resulting red uction (hypopnea) or cessation (apnea) of airflow (inspiratory flow limitation) produces dips in oxygen saturation, increases in inspiratory efforts against the obstructed airway, and sleep fragmentation .J These nocturnal physiologic events lead to a variety of neurophysiologic and cardiovascular complications, including daytime hypersomnolence, cognitive impairments, systemic and pulmonary hypertension, and cardi ac arrhythmias (figure 1). Several investigators have reported an increased risk of myocardial infarction and stroke associated with OSA. [2] [3] [4] Left untreated, moderate OSA increases the risk of death .'
Despite the serious consequences of this disorder, the actua l prevalence of OSA in the general pop ulation remains unclear. 6 Evidence does suggest that in the middleaged population, 4% of men and 2% of women have OSA .?There are three primary reasons why the extent of this common disorder has gone largely unrecognized until recently . First , there is no tight relationship between the number of abnormal respiratory events that occur during sleep and the subjective reporting of daytime symptoms by patients."For example, in a population study, Young et al found that 24 % of men and 9% of women had an apneahypopnea index (AHl) of 5 or more events per hour. ' However, only 4 and 2%, respectively, had this degree of sleep disordered breathing (SDB) in conjunction with daytime sleepiness and therefore met the criteria for the obstructive slee p apnea syndrome (OSAS). The difference between the two groups cou ld reflect individual differences in the way sleep frag mentation affects daytime function, or it might be that many indivi duals simp ly do not recognize their degree of sleep iness and therefore do not report it.
Second, there has been no general agreement as to what degree of SDB is abnormal. Therninimum number of events per hour of sleep that is considered to be significant by different sleep centers ranges from 5 to 15. Nor is it clear what degree of SDB is required to produce a specific clinical effect."This can make it difficult for the physician to determine when intervention should be offered. There is little question that the physician should treat a patient who has an AHI of 10 with accompanying significant daytime symptoms. But it is not clear if treatment is best for a patient with the same AHI but no symptoms.
Finally, as our understanding of this disorder evolves, so do our definitions. Twenty-five years ago, OSA was considered to be a rare disorder tha t was confined to the gross ly obese. Therapy, in the form of tracheostomy, was offered only to those who were in a life-threatening situation. Wit h the adve nt of more widespread and sophis-PIPER, STEW ART ......
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Partial to complete airway closure defined , recent epidemiologic evidence suggests that even low indices of SOB-for example, an AHI as low as 5 events per hour-are stati stica lly assoc iated with an increa sed incidence of hypertension and other cardiovascular events." The question of when to intervene still has not been clearly answered, but patients with increasing ly milde r levels of SOB are now being screened and treated . ticated testing, it became apparent that the full clinica l picture of OSAS does occur in patients who do not have frank apnea but who ex perience decreased airflow (hypopnea) and arousals from sleep, a set of symptoms .called the obstructive apnea-hypopnea syndrome. 10 By the early 1990s, Guilleminault et al descri bed patients who experienced sleep fragmentati on and daytime sleepiness, but who did not experience the obviou s apneic or hypopneic events that caused the brief arousals that were observed.I''P The se arousal s were attributed to an abnormal amo unt of inspiratory effort, a cause that was confirmed by the presence of high esophageal pressure swings. Known as the upperairway resistance syndrome, this disorder can occur in the absence of snoring (figure 2).12 Therefore, OSAS should be considered as a continuum of upper airway instab ility, ranging from simple snoring to severe, repetitive, complete airway closure . Aging and obesity push the predi sposed patient toward the severe end of the sleep apnea spectrum.
Even though the minimum leve l of SOB that must be present to pose a significa nt health pro blem has not been I ·Repet itive br ief arousals 1-"" 
Nasal CPAP therapy
The fundamental principle underlying the treatment of sleep apnea is that therapy will be successful if one eliminates the cause of the sleep d isruptio n. In order to achieve this, the airway must be stabilized, blood gas levels must be normalized , and inspiratory effort must be reduced ( figure 3 ).
Since its introduction in 1981, nasal continuo us positive airway pre ssure (CPAP) ha s become widely accepted as the treatment of choice for obstructive sleep apnea ." CPAP eq uipment acts as a pneumatic splint, creati ng positive pressure inside the airway throughout the respiratory cycle.14 One reaso n that CPAP is so effective in abolishing sleep apnea is that the pressure acts along the entire upper airway so that all potentially occluding segments are stabilized."
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Acute changes
Nursing Mothers: It isnot known whether triam cinoloneacetonideisexcreted inhumanmilk. 8ecauseother cort icosteroids are excretedin human m i l~caution shouldbe exercised lI11enNasacort Nasal Inhalerisadministeredtonursingwomen. PediatricU se;Sal e~andeffectPienessinpediatric patients below the age 016 havenot been e~a b~s he d. O ral corticost eroidshave beenshown t o ca use g r o,~h suppressioninch~d r e na n d t eena gers , particulanywith higher dosesoverextendedperi ods.Ifachildorteenageronany cort icosteroidappears tohivegr o ,~h suppressi on,thep os s i bi~t y thaftheyarep ar t i c u l ar~se ns~W e tothis effect01 steroidsshouldbe conSidered. ADVERSER EACnONS Adults andChildren12yea~of ageandolder.Incontrolledanduncontroll ed studies,1257adull andadolescentpatients recePied treatment withrnmnasal triamcinolone acetonide..Adversereacti onsare hasedonthe 567patientswho receW ed aproductsimilar 1 0the marketed Nasacortcanister. These patientswere treated loran average0148days (range1to 117 days). The145 patientsenr olledinuncontrolled sf udies receWed treatmentfrom1to820days (average 332 days!.Themost prevalentadverse expenence ,~s headac!Je, beingreport ed by ap prox i mate1 8%01 the pati ents 11110 receWed Nasacort. Nasallnilationwas reportedby l8%of the pati ents recemngNasacort .OthernasophOl)' ngeal side effects were reportedby fewerthan 5%01the patients who receWed Nasacortandincluded: dl)'m ucousmembranes, naso-sinus congestion, throat If l SCOm fort, sneezing,andep i s t axĩ Thecomplaints do not USl JaI~intertere withtreatment and inthecontroll edanduncontrolled studies apProxmat el y l % of pat i ent s ha,~l f l SCOl l ! i n ued becat J se o f t hese nasal adverse el ect s. l n theM nt ol m emal ovenl ose , an i ncreased pot el l l i al f or th~adverseexperi ences may be expected,but~em~adverse experiences areun l i k e~(see O VERDO SAGE section). CIltidren 6through 11 yea~01 age:Adverse event dm~chĩr en 6through11years of~are derived fromt -.~controlled clinical trials of tMl and lour"ms duratioQInthese trials, 1Z7 patients received fixed doses 01220 mCg/day oflriamcinoIooe aeetonxte lor an averageof22 days (range8t033 days). Shake Well Belore U sing 8RIE f SUM MARY CON TRAINOIC A TIO N S Hyp ers e ns~toany ofthe ingredients01 thispreparation contraindicates its use. WARNINGS. The r e~a cem ent ofasystem icco~er o i d ,nth atopical cor t i co~er~d can be accompanied by s~ns 01adrenal~sut l i ci ency and, inaddition, somepati ents may experience symptomsof,nthdrawal; e.g .,joint and/or muscular pain,~ss~e and depression. Patients p r evi o us~treated for prol onged penods ,nth~em i c co r t i~e r oi ds and transf err ed fo topical corticosteroids shouldbecarefuily m Ol l~o red loracuteadrenal insufOOency inresponse tostress.Inthose pati ents~o have asthma orother dinical COnditiOllS requiring long-teom~e m i c corticosteroid treatmenl too rap~adecrease insystemiccortĩe ro~s may cause asevere exacerllation01their,symptoms.
M.irse everrts
ChildrenII1lo are on inmul l OSUppressant drugs are more susce pl i~e toinfectioos than heaIIhy ctu'dren.Chickenpox and measies,lor example,can have amore seOOi Jsoreven fatal COllSl inchidren 011 immuoosuppressant doses ofcor t i cost ero xt~InSlJc!J ctuldren, orina: tu~1\1'/1 have not had these diseases, particular care s h ou~be ta \en toavo~exposure. nexposed. therapy ,nth vaJi cel~· z osre ri m m u l l O g l o bu~n (VllG) orpooled intraveoous immunogloMn(MG),as approjJIiate, may be iooJCa1ed.nch d<e~dMIops. treatment l'ith antiviraJ agerrts may be coosi!ered.
PREC AunON S G eneral: Inclinical studies wM triamcinolone acetonide na s~spray,the developmentof localized inlect ionsofthe nose andphal)' lOX wM candida afbicans'has r ar e~oCClJrred.lVhensuchan inlectiondevelops~mayrequiretreatmenl \ ' Ĩ h appropriate localorsystemictherapy anddiscontinuanceoftreatment withNasacortAQ Nasal Spray. Nasacort AQNasal Sprayshouldbe usedI'nth caution,natall,inpatierrts with active orquiescent tuberculous infection01 the respiratol)'tract orinpatientsI'nth untreated fungal, bactenal,orsystemicvi ral inlections orocular herpes simplex. BecauseoftheinhiMol)'effect01corti costeroids,inpatientswhohaveexperienced recent nasal septal ulcers, nasalsurgel)',ortrauma;a corticosteroid shouldbe u se d w~h cautionunti l healinghas oCCl Jrred.f>s with othernasally inhaledcorticosteroids,nasal septal pertorations havebeenreportedinrareinstances. \\1len used at excessive doses,~em i c corticosteroideff ects such as hyp e r co r t i c~m and adrenal suppressionmay a~p ear . Ifsuc!J changes OCCl Jr, Nasacort AQ Nasal Sprayshouldbedisconti nueds l ow~, co nsĩ e nt w~h acceptedproceduresfor disconti nuingoralsteroid therapy. Inf ormationlorPatients: Patientsbeing treatedwithNasacort AD Nasal Spray shouldreceivethe followinginlormationand instructions. Patientswho areonimm unosuppressant dosesof cort icosteroids shouldbewarnedtoavoidexposure tochickenpoxor measles and, if exposed,toobtainmedical ad,ice. PatientsshoulduseNasacort AQ N asal Sprayat regU lar int ervalssince~s effectiveness depends on~s regular use. (See DOSAGE AND ADMINISTRATION.)
An improvem entinsome patient symptoms maybe seenwithinthefirst day of treatment,andge n era l ,~fa kesoneweek oftreatmentto reac!J maximum !lenef rt. lnitial assessment lorresponse should be m adedunng thistimeframe and p e n od i ca l~unti lthe pati ent' ssymptoms are st abi le d .
Thepati entshouldtake the medicationas directed and shouldnotexceed theprescnbed dosage.The pati entshouldcontact the phys i c~n n symptoms donot improveafterthree weeks, oril the conditionworsens. Patienf swhoexpenence recurrent episodes ofepistaxis(nose bleeds)ornasal septum di scomfort whiletakingthismedicati onshoul dcontact their p hy s i c~n . Forthe r. roperuse ofthis u n~andtoattain maximumimprovement,thepatient shou~read andfollowthe accompanyingpatient instructionscare u l~. It isimport anttoshake the bottl ewellbeforeeac!J use.Also,lhebottleshouldbediscarded alfer 120actualions sinceIhe amounf 01triamciooloneaclionidedelW eredlIl ereafterperaduation maybe substantiallyless than 55 mcgof drug. 00 not transferany r e m~n i ng suspension toanotherbonle. C a~i n o g e n es l s , Mutagenesis,and Impaioment of ferti lity: Inatwo-year study inrats,~c i no l o ne aeetonide caused not reat rnent -re~ted ca r cj no ge n~i l y at oral doses upto1.0mcg!kg (app ro xi mat e~1130 and 1~of the maximum recom mended dailyintranasal dose inadults and chidren OIl arnq¥m' basis. respect i ve~) . ina~study inmte,triamanolone aeetonidecaused no t r eat r nel 1t -r e !ed caninogenicily at oral dosesupto3.0mJ:gil<g( approxi mate~1112 and 1130 ofthe maximum recommended da i~intranasal dose inaduna andc!Jildren on ameg/m ' basis, respectiveM· No m ut ag en i cĩ studies with triamcinoloneacetonide have been pertoomed. Inmaleand female rats, triamcinolone aeetonide caused no clJange inpregnancy rate atoral dOles up to15.0 mcg/<g (appro xim~~1/2 ofthe maximum recom mendedda i~int ranasal dose inadults on ameg/m' basis).T namcinoloneaeetonlde caused increasedletal resorptions and stillbirths and decreases inpup v ,~~ht and survival~doses ot 5.0 Jl 1C!l I<g and above (approximately 115 01 the maximum recom mended daily intranasal dose inadults onameg/m' basis).At 1. 0m C~Q (approxi mate~1130 01 the maximum recommendeddai~intranasal dose in adults on ameg/m' basis),~didnot induce the above menboned effects. Pregnancy: TeratogenicEffects:Pregnancy C ategoryC .Tr~m c i n ol o n e acetonidewasteratogenic inrats, rabbits,and monkeys.Inrats, triamcinolone acetonide , ,~s t erat oge n~ati n h a~t i o n dOles0120mJ:gi l <gand above (approximatett7110 01th emaximumrecom mended d a i~in mnasal dose inadults onam cg/ m' basis). In rabbits,triamanoloneacefonidewas terafogenl C~inhalati ondoses0120 mJ:gi l <gand above (approximatelj 2times the maxim umrecommeooed dai:yirtranasal dose~aduna on amCl)' m' basis).In monkeys,l ri amc~o ! one acelorJide I '~S teratogenic~aninhalafi ondose of500 mcgikg( a p proxi m ate~37times themaximumrecommended da ĩ intranasal dose inaduna on amcgIm' basis).Oose · re~t ed teratogeniceffects mratsandrabbits included deftp~t e and/ori n t e r nal l rf d roc epha~andaxial s\eietal delects, whereas theeffectsobservedinthemonkeywerecranial malfomnafions. Thereare no adequaleand well·controlledstudies inpregnant w om en.Therelore, triamcinolone ace ton~e shouldbeused inpregnancy only nthepo tent~b enefrt justilies thepotential nsktotheletus.Since thcirintroduction,experiencewM oral cor t i co~er o i ds inp hanm a co l og~a s opposedtophysiologiCdosessuggest sthat rodentsare more pronetoteratogenicenectsfromcorticosferoids thanhvmans.Inaddition, because lIl ere~anatural increase in g l u coco r t i co~produ ction duJi J1g pregnancy,most women,i O require a1 00verexogenous coiticosteroiddose andmanywill not needcorticosteroidtreatmentduring pr egnancy. Nonleratogeni eEIIects: Hypoadrenalismmayoccur ininfantsborn ofmothersreceivingcort icosteroidsduring pregnancy. Suchinlants s hou l d beca r el u l~obse rve d .
Nursing Mothers: It isnot known whethertnamcinolone acetonideisexcretedinhumanm ilk. Because ot her corticosteroids areexcretedin humanm il k,cautionshouldbe exercisedwhenNasacort AQ Nasal Spray isadministeredtonursingwomen. PediatricUse:Sal e~and effect Weness inpedi atric patientsbelowtheage016years havenot been established. C orticosteroidshave beenshol' mto cause growth suppression inc ! J i l ren andteenagers,particularty with higher doses overextended penods. IIachild or teenager OIl any cort icosteroidappearstohavegrowth suppressi o n, t h e po ss l b i l ĩ t h a t t hey a r e p ar t i c u l ar~sen si t i vet ot h l s ef f ec t 01corticosteroids should be considered. ADVERSEREAcnO NS Inp~ce bo-eo nt r o D ed , double-bfl nd,andoperrlabel clinical st uJf 1483 adults andchildren12years and o~e r receWed treatment I' ,illlirlamcinoione acetonide aqueous nasal spray.These patientswere treated foran average durati on01 51days.Inthe controll edtrials (2·5VleeKs duration) from which the loll o\' ring adverse reactiondmare derivea,1394 patients ¥rere treated vnth Nasacort AQ Nasal Spray loran average 01 19 days. Inalong·teom,open·label study,172 pati entsreceW edtreatmentloran average durati on of286 days. Adverse eventsoccurringat an incidence of2%or greater andmore common among Nasacort AQ ·treatedpatients than p~ceb o-t r ea t ed patients incontrolled adullcli nical trials ¥rere:
.
2.1 1. 5 Atotal of602 children 6to12 years 01 age were studied in3double-blind, placebo·controlled clinical tri als. Of these, 172 receWed 110meg/day and 207 recePied 220 meg/day of NasacortAQNasal Spray fortwo, sb<, or~, e l ve weeks.The longeat average durations 01 treatment for patients recemng110 mcg/day and 220 mcg/day were 76 days and 80 days,r es p e ctW e~. On~1%of thOle patientstreated ,nth Nasacort AQ mredisconti nued duetoadverse experiences.Nopati entrecemng 110meg/day discontinued due toasenousadverseevent and one patientrecemng220 meg/day discontinued due toasenous event that wasconsidered not drug related. Overall, thesestudies .found the adverse expenence profilefor Nasacort AQtobe similar top~ce bo . Asimilar adverseeventprofile,s observed inpediatric pati ents6-1 2years ofage as compared toolder children and adults ,nth the exception 01 epistaxis~i ch occurredinless than 2%01 the exp eri encing a treatment respon se with CP AP plu s conserv ative measures comp ared with conserv ativ e measures alone was 6.52. H istoricall y, CP AP therapy has bee n reco mme nded primaril y for patients who have moderate to severe OSA. However, with increased awareness and diagno sis of this disorder, therap y has been extended to patient s with mild disease, although, as ment ioned, the minimum level of disease severity at which patient s will deri ve benefit fro m therap y is still uncl ear. Engleman et al performed a rand omized, placeb o-controll ed study of34 pat ient s who experienced mild sleep apnea (AHI: 5-15 events/hr) and daytime slee piness .'? Th ey found that CP AP result ed in clini cally significa nt imp rovement s in subjective sleepiness and in health and functional status , eve n though effec tive CPAP use averag ed onl y 2.8 hour s per night. In a much larger study by Redl ine et al, patient s with mild disease who were rando mized to CPAP ex perience d a twofold im provement in we ll-being ove r those who were managed with conservativ e meas ures .20Furthermore, this study identified two subgroups of pati ent s in thi s setting who are most likely to benefit from CPAP intervention: those with an underlying co morbidity such as hypertension or diabetes and those with no history of sin us problem s. One of the maj or adva ntages that nasal CP AP has over other therapie s for OSA is that CPAP can be give n to a patient on a trial basis and easi ly modified or withdrawn if it is not tolerated or if the ex pected clini cal res po nse is not ac hieve d.
Determining CPAP pressures
In order to determine what level of CPAP is approp riate for an ind ividu al, a so-ca lled pressure titration is perfor med. Th e patie nt is fitted with an appro priately sized nasal mask and slee ps overnight with the mask in place . Whil e the pat ient sleeps, the pres sure is increa sed incrementally until apn eas , hypopn eas , sno ring, and de saturation are stopped. In the past, such a proc edure requ ired manu al altera tions in pressure by an atte ndant, who freq uently had to tend to an array of sensors that mon itored both sleep and breathin g parameters. Howeve r, recent improve ments in CPAP technology have Volume 78, Number 10 seen the developm ent of "au totitrating" de vices that use propri etary algorithms to autom atically alter the pressure in the presence of upp er airway instability. One such device, the AutoSet (ResMed Cor p., San Diego), incre ases pressure in res ponse to snore or flow limitation rather than waiting for hyp opn eas and apneas to OCCU r. 21 The Aut oS et does not require a techni cian to intervene when pressure alterations are needed . Th e CP AP pressure level s determin ed by this device have bee n shown to be co mparable with manu al titrat ion in patient s with uncomplic ated OS A. 2 2,23 Thi s techn ological dev elopment provides the opportunity for the proc edure to be performed in se miatte nded or unattended env ironments.
It is impor tant to realize that the first night of CPAP therapy will be strange and possibl y anxiety-provoking for the patient. Education regarding the need for CPAP therapy, as well as an ex planation of the purpose of the titr ation study, ca n help allev iate some of a patient ' s uncertainti es. A period of tim e with the mask in place at a low level of pre ssure (5-7 em HP ) can be useful in preparing pati ent s for the sensa tions they will experience whil e wearing a mask during sleep. Sle ep quality itself might be altere d during the first few night s of therap y; longer-than-normal durations ofboth slow-wave and rapid eye movem ent (REM) sleep are frequently obse rve d during this initi al treatment peri od. v' -"
Despite CPAP, daytime so mnolence per sists in so me patient s. Th is might be the result of poor co mpliance with therapy (as discussed later).26.27Alterna tive ly, the level of CP AP prescribed , although ap pro priate to eliminate apneas and hyp opneas, might be subtherapeutic if it does not also pre vent an elevation in upper airway resistance." The resulting flow lim itation increases the patient ' s wo rk of breathi ng. If this probl em is not identi fied , it can lead to an incomplete resolution of symptoms and poor comp liance. One possible difficulty is that CP AP titrati on is often performed using qualitati ve signals from senso rs, . suc h as thermi stors. Althoug h apneas and hypopnea s ca n be identified fro m such signals, flow limit ation ca nno t; this ca n result in the CPA P level being set inadvertently low. On the other hand , a pressure ca n also be set inappropri ately high, which can cau se problems relat ed to com- fort and side effects from airway dryness; this can, in turn , have an impact on the patient ' s willingness and ability to use CPAP . Even so, high press ures, whe n used appropriately, do not pred ispose to lower co mpliance." There appears to be no relation ship between the CPAP pressure required and difficulti es encountered .F:" Getting the correct pressure level is impo rtant, both in terms of the impac t that therapy will have on the patient' s clinical respo nse and in minimizi ng side effects.
In this co ntex t, a question might the n arise rega rding the acc uracy of a CP AP level base d on a single. night of titration. Va rio us fac tors-for example, weig ht change,'? nasal paten c y," and sleep state and body posit ionv-i-can all affect pressure requirements, not only within a single night, but from night to night. Several inves tigators have suggested th at pressure requirements would decrease from the initi al titration levels in time, with the resolu tion of traum atic upper airway ede ma and normalization of 782 REM duration.P-" However, a study by Teschler et al rece ntly demonstrated little change in pressure requirement s from the initial titration level at 3 and 8 mon ths' followup." These findings are in co ntras t wit h those of Ser ies et aI, who reported a dec rease in titr ation pressure of approx imately 20% over time. 34 One possible explanation for these differe nt results could lie in the way the two groups determin ed pressure levels. Series et al used manual titration, while Teschl er et al used an autotitrating system, whic h acted to elimi nate flow limitation as well as snoring and apneas.
Side effects
Minor side effec ts with nasal CPAP are commo n, with up to 40 to 50 % of patie nts who comme nce therapy complaining of at least one side effect.P:" Although these problem s are ge nerally minor in natur e, they neverth eless can be distressing enough for the patient to lim it the use * For susceo Ible s rains01 IndICated organisms Augmen/ln IS aoprconate ,"'lIal therapy wnen you suspec Il-Iac a se-orooocmq pathogens Please see briel summary 01 presc ribing Informalion on adjacent page lor contra Indications. warnings. precautions. adverse reactions. and dosage and admin istration. should betaken at thestartofa meal.
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PIPER. STEWART of therap y, part icul arl y if the patient has experienced few daytim e symptoms as soc iated with sleep apn ea. Englem an et al found that CPAP use by patien ts who reported probl em s was ab out only 60 % of that repor ted by pati ent s who did not co mpla in of pro blem s with CP AP . 35 These fi ndings emp hasize the importance of the early recognition of any problems that could arise from using CPAP and the necessity of dealin g with these iss ues prom ptl y (table) .
In ea rly studies, pai n and skin breakd own over the brid ge of the nose was co mmo n, occ urr ing in up to 30% of patien ts." Th ere is now a wide ran ge of mask sizes and styles available so that an appropriate fit and sea l should be achieve d in mo st pat ient s. Features such as silicon flaps and bubbl es over the mask cushion are useful in reducing leakage into the eyes and minimizin g the amount of pressure required to ac hieve a seal between the cushion and the patient's ski n. Attentio n to findi ng a ma sk that the patient finds comfortable and that has minim al leakage is key to establishi ng long-t erm acceptance of therap y. Few indi vidual s will co ntinue to wea r a mask if they have painful open sores over the nasal bridge or if air is rush ing into their eyes.
Several studies have show n that there is no correlation betw een the fre quency of repor ted side effects and the level of pressure." > Not surprising ly, the o ne factor that does appear to affect CPAP use is claustrophobia." In such indivi duals, cha ng ing the mask style might be effective. Ligh tweight , transparent masks are now available; patient s with claustro pho bia co uld find these easier to tolerate than the o lder, more solid masks. Nasal pill ows, where interface co ntac t with the patien t is only around the nostrils, might also be of benefit in th is pat ient gro up.
Mou th leaks are co mmon and are respon sible for a large number of uncom fortabl e side effec ts. T he main probl em is related to airway dryin g, which might be problem at ic enough to affect nasal CP AP use." Co mplaints include rhinitis, nasal co nges tio n, mouth dryn ess, and sore thro at. Wh ere leaks are small, a chinstrap ca n main ta in a more effective lip seal and mig ht minimize sympto ms. However , when a leak is large and persistent , heated humidification is the most effec tive means of redu cin g patient discomfort. 37 Occasionall y, pati ent s co mplain of chest dis co mfor t durin g or followi ng therapy. Th is d iscomfort is musculoskeletal in nature and is suggested to be seconda ry to the elev atio n of lung vo lume dur ing pos itive pressure." It might be relieved by lowering the pres sur e fo r a perio d while the patient acc limatizes .
Signi ficant co mplications from CPAP therapy are rare,' but there are case reports of massive epis taxi s," atrial arrhythmia," and pneu om ocephalus."
Compliance w it h therapy
Although CPAP is highly effective in eliminating obstructive eve nts during sleep, its effectiveness can be Table. Common problems related to the use of nocturnal nasal CPAP and some of the possible management strategies limited by incompl ete patient acceptanc e of and comp liance with ther apy. Among unselected OSA patients, acceptance of CPAP ther apy has ranged between 50 and 90%.28.42.4 3 Studi es of self-reported data sugges t that 75 % of patients who use CPAP do so on a daily basis" for at lea st 6 hours a night." However, such subjective data are known to be notoriously inacc urate, as patient s co nsistently overestimate their CPAP use. Using covert, obje ctive measurements of CPAP use and duration, Kribb s et al found that while 60% of the patients they studied claimed to have used CPAP nightl y, only 46 % met their criteria for regula r use, which they defined as at least 4 hour s per night durin g 70 % of monitored night s." The mean duration of CPAP use in the Kribb s study was 4. 8 found the mean duration of CPAP use to be around 4.7 to 5.6 hours per night. 28 . 35 .42 Alth ough not a universal finding, it see ms that patients who are objec tively sleepier at baseline are more likely to be better users of CPAP. 26.29,44 Th is trend supports the notion that relie ving daytime sym ptoms is a positive motivator for the continued use of CPAP. A numb er offactors have been identified as having a negative impact on CPAP use, including the absence of hypoxemia" and previous palatal surgery .P:" Alth ough patients are usually instruct ed to use CPAP duri ng any major sleep period on a daily basis, it appea rs that many use it only intermittently. Some investigator s have sugges ted that it might not be necessary to use CPAP on such a reg ular basis to attain clinical benefit." However, regular use does appear to impro ve breathing dur ing sleep; one study reported that SDB was an average of 35 % less severe durin g 1 night of CPAP withd rawal than it was at baselin e." It is thought that long-term CPAP therapy might improve airway stability throu gh a number of mech anisms, including a reduction in upper airway edema, resoluti on of chronic sleepiness , and impro ved nocturnal oxyge n saturation. Other inves tigators have found that when CPA P was discontinued after 4 hour s of sleep, its benefit in terms of oxyge n level and sleep qualit y remained throu ghout the night ." These findin gs support those of Engleman et al, who demonstrated that even after an average of only 4 hours of CPAP use, there were improvement s in subje ctive reports of daytime symptoms, as well as objective measurements of daytim e sleepiness .'? It appears then that eve n though many patient s use CPAP at a level less than that prescrib ed, its use is probably titrated to achieve a satisfactory degree of symptomatic relief. Indeed, there are some patients who use CPAP for less than 3 hour s per night and yet are still satisfied with therapy." Furth er studies are warranted to determine if there is a level of CPAP use below whi ch longer-t erm benefit s are not achieved.
What can be done to improve compliance by patient s who requ ire long-term therapy? Chervin et al found that simple interventions, such as frequent phone followup and brief written i nstructions rega rding CPAP use, could be effective in improvin g compliance ." The y reported that pati ent s who receive d these interve ntions used CPAP an average 1.3 and 2.7 hours longer, respectively, than did control subjects who were not pro vided with such interventions . Furth ermore, they found that these inter ventions were more effec tive in those individuals who were about to start CPAP than in those who were already on therapy. How patients are introduced to therapy, and the followup and support they receive durin g the first few weeks, are crucial to maximi zing the likelihood of pat ient acceptance of therapy and is a major determin ant of CPA P use in the longer term. 17 In a recent study by Hoy et aI, it was show n that intensive support-including a supervised 3-night trial of CPAP followed by home visits-in add ition to the standar d support significantly improved CPAP use and outco mes compared with those see n in patients who underwent standard support -grou p care (initial education, phone ca lls, and clinic visi ts)." These results clearly point to the need for ear ly follow up and ongoi ng support to monitor clinical response to therapy and to promptl y ident ify and manage any problems.
Technological strategies for improving compliance and comfort One crucial factor must be taken into acco unt when one assesses the patient compli ance data reported in the literature: CPAP techn olo gy has impro ved dram atic ally durin g the past few years. Great strides have been taken in the developm ent of better patient interfa ces, a key aspect of compliance. In addition, the availability and import ance of heated hum idific ation to reduc e nasal res istance is now better appreciated." Finally, nasal CP AP devices now have better pre ssure-fl ow characteristics.
Althoug h these significant changes in techn ology are expec ted to imp rove compliance, prospective studies to determine whetherthey actually have done so have not ye t been publi shed. Many studies have foc used atte ntion on the physical side effec ts that co uld arise with CP AP use; psychosocial factors such as inco nve nience, ex pense, and claustrop hob ia can also pose prob lems for patien ts. Certainly, device manu factu rers have recognized patients' early complain ts abo ut machine noise, and most dev ices are now remarkabl y quiet. In fac t, the loudest noise now is made by air bein g vented from the ex halatio n port s on the mask. Mo reover, the devices are now much smaller and more co mpact than ear lier models, mak ing them less intru sive on the patient ' s lifestyle, part icul arl y for those indiv iduals who travel reg ularly. Today' s CPAP devices also incorp orate a number of new design features, such as delay timers and ramp s, that might playa role in improving co mpliance.
Ramping. Ramping, a feature that is now routin ely includ ed in most CP AP devices, is a method of slow ly increas ing the airway pressure level to its setpo int over a period of 5 to 30 minutes. Th is feature can assist the patient who might perceive higher CPA P pressures as uncomfortable while awake, but who both to lerates and requires the higher pressure levels durin g slee p. By progressive ly ramping the pressure up, a patient ca n become acc ustomed to the gradual sensation of increased pressure
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Humidification. Nasal co nges tion and dryin g of the airways affect between 30 and 50% of patient s who use CP AP , and for so me the discom for t is severe eno ugh to reduce co mpliance. 26 Th ese sy mptoms are related to mo uth leaks. Th e degree of mouth leak that occurs with CPAP use depends on several fact ors, includi ng the pressure in the mask , nasal res istance, and the degree to which the mouth opens duri ng slee p." At CP AP pressur es above 10 em H 2 0 , leak s greater than 40 to 60 Umin are not uncommon , although they can be difficul t to assess clinica lly." Som e of the newer auto titrating de vices are able to continuously measur e lea ks during CPA P application, prov iding the clinician with an objec tive ind icator of the freque ncy and severity of such leaks. Rich ard s et al dem onstr ated that mouth leaks during the appl ication of nasal CPAP resulted in sy mptoms of nasal drying, followed by nasal co nges tion and increased nasal sec retions." As a co nsequence, nasal resistance increased substantially . However, these authors dem onstrat ed that with heated humi difi cation, nasal symptoms and alterations in nasal resistance could be largely prevent ed . Th ere are now co mme rcia lly avai lable heated hum idi fi-cation sys tems for CPAP devices. Alth ough no study has looked at differenc es in CPAP use whe n patients with sympto ms are placed on humidificati on , clinical rep orting indicates substantially greater pati ent com fort with hum idification. The oreticall y, the use of humidification , whi ch prevent s increases in nasal res istance, should improve the amo unt of positive pressure deli vered to the oro phary nx , rende ring CP AP therapy more effective.
Bi/evel pressur e. Bile vel devic es permit the patient to indep end entl y adj ust the inspi ratory and ex piratory pre ssure levels. Th ese de vices have not been show n to alter co mpliance in patient s with uncomplicated OSA .50Ho wever, for patient s with hyp ercapni a during wak efulness and for those wh o have coexisting lun g di sea se, the se devices not only imp rove breathing co mfor t, but by offering a boost to inspiration the y also assist ve ntilatio n and low er ca rbo n dioxide level s. Wh en setting bilevel therap y, it is imp ortant to set the ex piratory po sit ive airway pressure at a level that is sufficient to ensure that airway paten cy is maintained . Failure to do so will cause a part ial or complete airwa y clos ure, and result in either the reappearance of sy mptoms or an inadequate blood gas im- Autotitrating CPAP . The concept behind autotitrating CPAP devices is that the amount of pressure required to eliminate events can vary from night to night. Autotitrating devices vary the pressure level s within a night , as well as from night to night , in response to changes in nasal obstruction, sleep stage, a nd body position . There are a number of potential uses and advantages of these devices in titration and in the followup of patients who require nasal CPAP therapy. In those individuals who have variable pressure requirements during a night , overall mean airway pressures can be reduced bec ause pressure would be increased only when required." By reduc ing pressurerelated side effects, comfort and compliance should be impro ved.
Likewi se, individuals who have seasonal rhinit is might benefit from an autotitrating device becau se pressure is automatically increased when nasal resistance is high, . then reduced again when nasal patency impro ves. In those patients who are already established on therapy, an autotitrating device can be used over a period of time in a patient' s home to determine if the prescribed pressure level remains appropriate. Because this technology is still evolving, it must be borne in mind that not all autot itrating devices work in the same manner; some use more sophisticated algorithm s to both measure upper airw ay events and respond to them." Var iations in the design of these systems might influence patient outcomes, so clin icians need to be aware of how an individual device operates in order to evaluate the information that is der ived from them . 
